LIEGE, Belgium, Oct. 25, 2017 — Nexeon MedSystems Inc (OTCBB: NXNN) announced its completion of an initial series of clinical studies evaluating the utilization of transcutaneous auricular vagus nerve stimulation (aVNS) for the relief of paroxysmal atrial fibrillation. The Company was previously awarded a €3.4M research grant in relation to this study from the Walloon Region government of Belgium in coordination with the region’s health competitiveness cluster BioWin.
Nexeon’s Director of Clinical Research Dr. Navid Khodaparast commented on the study’s preliminary results as follows, “Our aVNS system supported our original hypothesis by demonstrating a significant stimulation-induced effect on heart rate variability, which may prove to be effective in treating atrial fibrillation. It is our belief that a more holistic approach to the application of neurostimulation will usher in a new era of neuro-technological advances. While our near-term target is to discover an improved therapy for patients with atrial fibrillation, we recognize the greater implication of monitoring, and potentially modulating, signals from the heart in a population of patients suffering from chronic diseases who are managing multiple comorbidities.”
Next steps related to this clinical program will be the completion of a study on twenty patients suffering from paroxysmal atrial fibrillation. The protocol includes an assessment of therapeutic safety and feasibility while participants receive chronic aVNS.
VNS has been used for years to treat epilepsy. Researchers worldwide are investigating whether delivering pulses of electricity to the nerve can help treat tinnitus, stroke, headache, asthma, obesity, depression, Crohn’s disease, and more.
About Nexeon MedSystems Inc: Nexeon is a global bioelectronics medical device company focused on providing innovative neurostimulation products that improve the quality-of-life of patients suffering from debilitating neurological diseases.
Forward-Looking and Cautionary Statements: Statements in this press release that are not strictly historical may be “forward-looking” statements, which involve risks and uncertainties, and Nexeon undertakes no obligation to update any such statements to reflect later developments. These risks and uncertainties include Nexeon’s ability to successfully complete on the terms and conditions contemplated, and the financial impact of, its strategic portfolio repositioning actions, as well as economic and currency conditions, market demand, pricing, protection of intellectual property, and competitive and technological factors, among others, as set forth in Nexeon’s subsequent reports filed with the SEC.